Home » Clinical Trials » Leukemia » NCT03327285
NCT03327285

A Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Subjects With Acute Lymphoblastic Leukemia(ALL) After Hematopoietic Stem Cell Transplantation（HSCT）

Study Summary

This is a single-center, prospective clinical study evaluating safety and efficacy of C-CAR011 treatment in subjects with ALL after HSCT

Want to learn more about this trial?

Request More Info

Interventions

C-CAR011BIOLOGICAL
CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)

Study Locations

FacilityCityStateCountry
Peking University Institute of HematologyBeijingBeijing MunicipalityChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026